Who are NITROGLYCERIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Monoket, Nitroglycerin, Isobide, Cynara Scolymus, Nitroglycerin patch, Monoket Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nitroglycerin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

NITROGLYCERIN — Competitive Intelligence Brief

NITROGLYCERIN (NITROGLYCERIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrate Vasodilator [EPC]. Area: Metabolic.

marketed Nitrate Vasodilator [EPC] Nitric oxide synthase pathway Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

NITROGLYCERIN (NITROGLYCERIN). Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NITROGLYCERIN TARGET	NITROGLYCERIN		marketed	Nitrate Vasodilator [EPC]	Nitric oxide synthase pathway	1981-01-01
Monoket	ISOSORBIDE MONONITRATE		marketed	Nitrate Vasodilator [EPC]	Atrial natriuretic peptide receptor 1	1991-01-01
Nitroglycerin	glyceryl trinitrate	Fougera	marketed	Nitrate Vasodilator [EPC]	guanylate cyclase	1981-01-01
Isobide	ISOSORBIDE	Novartis	marketed	Nitrate Vasodilator [EPC]		1974-01-01
Cynara Scolymus	Cynara Scolymus	Stefan Fischli	marketed	Nitrate Vasodilator [EPC]
Nitroglycerin patch	Nitroglycerin patch	GF Strong Rehabilitation Centre	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Monoket Pill	Monoket Pill	Ohio State University	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-03-12 — Nitroglycerin · 7872049 · US
2029-03-12 — NITROGLYCERIN · 7872049 · Formulation · US
2032-03-11 — Nitroglycerin · 9101592 · US
2032-03-11 — NITROGLYCERIN · 9101592 · Formulation · US

Sponsor landscape (Nitrate Vasodilator [EPC] class)

· 2 drugs in this class
Centre for Addiction and Mental Health · 1 drug in this class
Fougera · 1 drug in this class
Novartis · 1 drug in this class
Stefan Fischli · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NITROGLYCERIN — Competitive Intelligence Brief. https://druglandscape.com/ci/nitroglycerin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab